Inmagene is developing differentiated therapies for immunological and inflammatory diseases using its proprietary QuadraTek® platform, which optimizes safety and efficacy. The company targets conditions such as atopic dermatitis and alopecia areata by inhibiting the OX40/OX40L signaling pathway to improve patient outcomes.
Funding
$216M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFounders
Product
Problem
Immunological and inflammatory diseases often require therapies with improved safety and efficacy profiles. Current treatments may not adequately address the underlying mechanisms of these diseases, leading to suboptimal patient outcomes.
Solution
Inmagene is developing a new generation of therapies for immunological and inflammatory diseases, leveraging its proprietary QuadraTek® platform to optimize safety and efficacy. Their lead candidates are engineered to address a broad spectrum of immune and inflammatory indications. The company is targeting conditions such as atopic dermatitis and alopecia areata by inhibiting the OX40/OX40L signaling pathway. This approach aims to deliver differentiated treatments with the potential to offer better outcomes to patients.
Target Audience
The primary target audience includes patients suffering from immunological and inflammatory diseases, as well as healthcare professionals seeking more effective and safer treatment options.
Features
- QuadraTek® platform for optimizing safety and efficacy of therapies.
- Focus on inhibiting the OX40/OX40L signaling pathway.
- Development of treatments for atopic dermatitis and alopecia areata.
- Engineered lead candidates to address a broad spectrum of immune and inflammatory indications.